02nd week of 2011 patent applcation highlights part 34 |
Patent application number | Title | Published |
20110008270 | COMPOSITION CONTAINING A WATER-MISCIBLE LIQUID AND A WATER-SOLUBLE PARTICLE, METHOD OF PRODUCTION AND USE THEREOF - The invention relates to a water-soluble composition comprising a water miscible liquid and water-soluble particles, the water-soluble composition being essentially free of water. The composition can be used e.g. as dental composition, cleaning agent, polishing agent, tongue surface cleaning agent or peeling agent. | 2011-01-13 |
20110008271 | ROSACEA TREATMENTS USING POLYMETAL COMPLEXES - Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds. | 2011-01-13 |
20110008272 | Use of Creatine or Creatine Compounds for Skin Preservation - The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system. | 2011-01-13 |
20110008273 | METHODS OF SKIN WHITENING AND OF SCREENING SKIN-SPOT-FORMATION INHIBITING AND/OR SKIN-SPOT REMOVING FACTOR - A method of skin whitening is provided which includes: selectively activating proliferation and/or differentiation of melanin-containing keratinocytes of the skin. | 2011-01-13 |
20110008274 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE FIXING POLYMER AND AT LEAST ONE AMPHOTERIC STARCH - A cosmetic composition for the treatment of keratinous fibres, in particular hair, comprising at least one fixing polymer and at least one amphoteric starch and the process for treatment of keratinous fibres using said composition. | 2011-01-13 |
20110008275 | METHODS OF CLEANSING DYED HAIR - Provided are methods of cleansing dyed hair comprising applying to dyed hair a composition comprising anionic surfactant and a hydrophobically-modified polymer capable of binding surfactant thereto. | 2011-01-13 |
20110008276 | ETHYLENEOXIDE BUTYLENEOXIDE BLOCK COPOLYMER COMPOSITIONS - The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated. | 2011-01-13 |
20110008277 | POLYOL-BASED POLYMERS - The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or maltitol) condensed with polycarboxylic acid units (e.g., citric acid, glutaric acid, or sebacic acid). The inventive polymers may be further derivatized or modified. For example, the polymer may be made photocrosslinkable by adding methacrylate moieties to the polymer. | 2011-01-13 |
20110008278 | MODULATORS OF PARAPTOSIS AND RELATED METHODS - The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound. selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (RMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell. | 2011-01-13 |
20110008279 | Methods and Compositions Relating to Adhesins as Adjuvants - This invention is in the field of immunology and relates to the discovery that adhesins are potent activators of dendritic cells. | 2011-01-13 |
20110008280 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2011-01-13 |
20110008281 | CARDIOPROTECTIVE ROLE OF HEPATIC CELLS AND HEPATOCYTE SECRETORY FACTORS IN MYOCARDIAL ISCHEMIA - The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and/or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and/or MMP-2). | 2011-01-13 |
20110008282 | IL-1alpha immunization induces autoantibodies protective against atherosclerosis - Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment. | 2011-01-13 |
20110008283 | INTERFERON FUSION PROTEINS - The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers. | 2011-01-13 |
20110008284 | NOVEL CLYCLOSPORIN ANALOGUES - The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 2011-01-13 |
20110008285 | NOVEL CYCLOSPORIN ANALOGUES - The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 2011-01-13 |
20110008286 | NOVEL PROLINE SUBSTITUTED CYCLOSPORIN ANALOGUES - The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections. | 2011-01-13 |
20110008287 | METHODS AND MEANS FOR THE TREATMENT OF HPV INDUCED INTRAEPITHELIAL NEOPLASIAS - The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the anogenital tract, such as HPV induced vulvar, cervical, vaginal, penile and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+ response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response. | 2011-01-13 |
20110008288 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-01-13 |
20110008289 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE - The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof. | 2011-01-13 |
20110008290 | METHOD FOR PREDICTING THE THERAPEUTIC RESPONSIVENESS OF PATIENTS TO A MEDICAL TREATMENT WITH AN INTERFERON - A method for predicting a response of a patient to a medical treatment with interferon, wherein the method includes detecting the allele identity of a polymorphism in the OAS1 gene in a nucleic acid sample previously obtained from the patient, and optionally detecting the allele identity | 2011-01-13 |
20110008291 | Use of antifungal compositions to treat upper gastrointestinal conditions - The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms. | 2011-01-13 |
20110008292 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACIDS ENCODING FRUCTO-OLIGOSACCHARIDE UTILIZATION COMPOUNDS AND USES THEREOF - Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed. | 2011-01-13 |
20110008293 | DEVICE AND METHOD FOR PREPARING MICROPARTICLES - The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles. | 2011-01-13 |
20110008294 | METHODS FOR TREATING CANCER WITH MVA - The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus. | 2011-01-13 |
20110008295 | SIMIAN ADENOVIRUSES SADV-36, -42.1, -42.2, AND -44 AND USES THEREOF - A recombinant vector comprises simian adenovirus 36, simian adenovirus 42.1, simian adenovirus 42.2 and/or simian adenovirus 44 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-36, -42.1, -42.2 or -44 gene(s) is also described. Methods of using the vectors and cell lines are provided. | 2011-01-13 |
20110008296 | MUSCLE-DERIVED CELLS HAVING DIFFERENTIATION CAPACITIES - The present application relates to cell populations having differentiation capacities, which are obtainable by isolation from a muscle tissue, more particularly from a skeletal and/or cardiac muscle tissue, preferably from endomysial and/or cardiac tissue, more preferably from endomysial tissue. The cell populations of the invention comprise ALDH-positive cells, and notably have myogenic and/or adipogenic and/or osteogenic differentiation capacities. | 2011-01-13 |
20110008297 | OXYSTEROLS FOR ACTIVATION OF HEDGEHOG SIGNALING, OSTEOINDUCTION, ANTIADIPOGENESIS, AND WNT SIGNALING - Synthetic oxysterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders. | 2011-01-13 |
20110008298 | METHOD OF DERIVING PROGENITOR CELL LINE - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line. | 2011-01-13 |
20110008299 | TREATMENT OF PELVIC FLOOR DISORDERS WITH AN ADIPOSE-DERIVED CELL COMPOSITION - A method for treating a pelvic floor disease comprises removing adipose tissue from a patient, processing a first portion of the adipose tissue to obtain a heterogeneous mixture of cells that includes adipose-derived stem cells, combining the heterogeneous mixture of cells with a second, unprocessed portion of the adipose tissue in a ratio of from approximately 1:1 to 1:4 to produce a cell composition, wherein the second portion of the adipose tissue is structured to provide a natural scaffold, and administering the cell composition to the patient to treat a pelvic floor disease. | 2011-01-13 |
20110008300 | Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells - The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining a high viability of the stem and/or progenitor cells obtained from the cryopreserved adipose tissue. Furthermore the cryoprotection medium of the present invention does not contain any kind of xenogeneic sera, a critical factor since it is the intention of that the cryopreserved tissue is used for obtaining stem and/or progenitor cells that can be used in medicine. The cryoprotection medium is characterized in that it is a solution of physiological water comprising glycerol and sucrose and/or trehalose and optionally serum albumin. | 2011-01-13 |
20110008301 | HUMAN ADIPOSE DERIVED INSULIN MAKING MESENCHYMAL STEM CELLS FOR TREATING DIABETES MELLITUS - The invention provides a novel therapeutic composition comprising of insulin producing mesenchymal stem cells obtained from human adipose tissue along with Hematopoietic stem cells for the treatment of diabetic patients especially insulinopenic patients. The invention also describes a simple and efficient process for the isolation, proliferation and differentiation of insulin producing mesenchymall stem cells from human adipose tissue. Unfiltered extract of adipose tissue is used in the process with a medium totally free from xenogenic material; the serial passages of the cells are avoided in the process. | 2011-01-13 |
20110008302 | Compositions and methods for immortalizing cells and screening for anti-cancer agents - An embodiment of the invention provides methods and compositions for immortalizing cells, and in another embodiment for reversing immortalization of cells. Methods for screening for anti-cancer agents by identifying compounds that bind to and inhibit activity of an Ndy protein are also provided. Novel cancer diagnostic and prognostic methods using Ndy1, Ezh2 and miR-101 are shown with samples of tissue or cell lines from cancers of lung, colon, ovary, bladder and transitional cell carcinoma. | 2011-01-13 |
20110008303 | METHODS FOR TREATMENT AND PREVENTION OF MRSA/MSSA - Described herein are methods for treating and preventing MRSA/MSSA. The present subject matter deviates from current treatment methods by introducing a controlled decolonization/recolonization method, which eradicates the host surface area of MRSA/MSSA, and colonizes the newly cleared surface area with a nonpathogenic or pathogenic bacteria capable of out-competing MRSA/MSSA. | 2011-01-13 |
20110008304 | USE OF CELLS TO FACILITATE TARGETED DELIVERY OF NANOPARTICLE THERAPIES - The present invention is related to the use of cells, such as stem cells or immune system cells, to deliver nanogels comprising an active agent to a desired site in the body. The present invention utilizes cells as a delivery system for active agents that are difficult to deliver, such as active agents with poor solubility, that degrade easily, or that are toxic to the body. The nanogels are preferably non-toxic and can optionally include a lytic agent to program apoptosis of the cell to deliver the nanogel and active agent to a desired sire within the body. | 2011-01-13 |
20110008305 | NANO-EMULSION COMPOSITION OF COENZYME Q10 - The present invention provides a nano-emulsion composition of CoQ10 comprising 5 to 20 wt. % of CoQ10, 1 to 5 wt. % of ethanol, 1 to 5 wt. % of lecithin, 20 to 30 wt. % of caprylic/capric glyceride or vegetable oil(s), 10 to 20 wt. % of glycerin, 1 to 15 wt. % of coemulsifier(s) and the balance of water. The present invention also provides a nano-emulsion composition of CoQ10 comprising 5 to 20 wt. % of CoQ10, 1 to 5 wt. % of ethanol, 20 to 30 wt. % of caprylic/capric glyceride or vegetable oil(s), 1 to 25 wt. % of emulsifier(s), 10 to 20 wt. % of glycerin, and the balance of water. The nano-emulsion composition according to the present invention can preferably improve stability, in vivo penetration, absorptiveness and bioavailability of CoQ10. | 2011-01-13 |
20110008306 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject. | 2011-01-13 |
20110008307 | Cephalotaxine Alkaloid Compositions and Uses Thereof - A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes. | 2011-01-13 |
20110008308 | Composition for hair, skin, nails - A pharmaceutical composition for use in hair, skin and nail health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists of a daily intake of 1 tablet that consists of: 5 mcg Vitamin D3, 40 mg Vitamin E (natural source), 60 mg Vitamin C, 8 mg Thiamin (vitamin B1), 4 mg Riboflavin (vitamin B2), 18 mg Niacin (vitamin B3), 10 mg Vitamin B6, 500 mcg Folic Acid, 9 mcg Vitamin B12, 45 mcg Biotin, 40 mg Pantothenic Acid, 12 mg Iron, 75 mg Magnesium, 15 mg Zinc, 200 mcg Iodine, 0.5 mg Manganese, 1 mg Copper, 50 mcg Chromium, 100 mcg Selenium, 10 mg L-Cystine, 2 mg Natural Mixed Carotenoids, 15 mg Grape Seed Extract (95% proanthocyanidins); plus 1 Nutri-dermal softgel capsule that consists of: 300 mg Omega-3 Fish Oil, 6 mg Lutein, 200 mg Starflower Oil, 50 mg Blackcurrant Seed Oil, 4 mg Lycopene, and 5 mg Coenzyme Q10. | 2011-01-13 |
20110008309 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2011-01-13 |
20110008310 | METHODS AND COMPOSITIONS FOR MITOCHONDRIAL REPLACEMENT THERAPY - The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities. | 2011-01-13 |
20110008311 | Animal Model and Use of 17Beta-Hydroxysteroid Dehydrogenase Type 7 in the Diagnosis of Anencephaly - The present invention features a non-human animal in which is deficient in the expression of endogenous 17β Hydroxysteroid Dehydrogenases Type 7 and use of the same in screening methods for agents that prevent or treat anencephaly. The present invention also provides a method for diagnosing and treating. | 2011-01-13 |
20110008312 | RADICAL THERAPEUTIC AGENT FOR KELOID AND HYPERTROPHIC SCAR - An effective therapeutic agent for keloids and/or hypertrophic scars is provided. Specifically, an elastic fiber regenerating agent consisting of chondroitinase ABC derived from | 2011-01-13 |
20110008313 | tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS - The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser | 2011-01-13 |
20110008314 | METHODS OF AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF MAMMALIAN CELLS - A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity. | 2011-01-13 |
20110008315 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 2011-01-13 |
20110008316 | Biological bioadhesive compositions and methods of preparation and use - The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride. The invention further relates to a novel method of using the improved fibrin sealant whereby the sealant and accompanying agent(s) are delivered directly to a critical site within the body and sealed in place due to the bio-static quality of the sealant. This provides therapeutic value to patients through prolonged presence, and optionally time-released delivery, of the specific agent(s) at the critical site. | 2011-01-13 |
20110008317 | CHARCOALS - Non-activated charcoals from living plant materials are useful as ion exchange agents for adsorbing cations from an environment, especially metal ions. | 2011-01-13 |
20110008318 | TOLL-LIKE RECEPTOR 5 LIGANDS AND METHODS OF USE - The invention provides an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence GAVQNRFNSAIT, or a modification thereof, and having toll-like receptor 5 (TLR5) binding. Methods of inducing an immune response are also provided. | 2011-01-13 |
20110008319 | CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE - The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods. | 2011-01-13 |
20110008320 | Further Use of Protein Kinase N Beta - The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway. | 2011-01-13 |
20110008321 | Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 2011-01-13 |
20110008322 | ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHODS - The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and either at least one HER2 or at least one EGFR antibody. In some embodiments, the antibodies are administered with a therapeutic agent. The present invention is further directed to C35, HER2 and EGFR antibodies useful in these methods. | 2011-01-13 |
20110008323 | Cadherin-11 EC1 Domain Antagonists for Treating Inflammatory Joint Disorders - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 2011-01-13 |
20110008324 | Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof - An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 2011-01-13 |
20110008325 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension - An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of corticosteroid, such as budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, in solid or liquid (dissolved) form, with an inhalable suspension-based unit dose formulation. | 2011-01-13 |
20110008326 | BINDING AGENTS DIRECTED AGAINST IL-4 RECEPTOR FOR THE TREATMENT OF TUMORS, INFLAMMATORY AND IMMUNOLOGICAL DISORDERS - The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders. Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods for treatment and/or prevention of tumors, inflammatory and immunological disorders, the methods comprising administering to an individual in need thereof an antigen-binding agent with binding affinity for IL-4R. | 2011-01-13 |
20110008327 | COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2011-01-13 |
20110008328 | METHOD FOR CONTROLLING GLUCOSE UPTAKE AND INSULIN SENSITIVITY - The invention provides methods for treating diabetes and related disorders, such as metabolic syndromes (which includes insulin resistance), by administering an inhibitor of osteopontin (OPN), which includes an antibody, antibody fragment, siRNA, and aptamer. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of OPN. | 2011-01-13 |
20110008329 | Methods of Treating RSV Infections And Related Conditions - The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient. | 2011-01-13 |
20110008330 | Compositions and methods of tolerizing a primate to an antigen - Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen. | 2011-01-13 |
20110008331 | USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE - The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer. | 2011-01-13 |
20110008332 | Combination Therapy to Treat Persistent Viral Infections - The present invention pres ides combination therapies to treat persistent viral infections. In particular, combinations of vaccines and IL-10 or IL-10 receptor (IL-10R) antagonists to clear such infections are provided. | 2011-01-13 |
20110008333 | METHODS OF INHIBITING UNWANTED CELL PROLIFERATION USING HEDGEHOG ANTAGONISTS - The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein. | 2011-01-13 |
20110008334 | NOGO-A BINDING WITH ENHANCED AFFINITY AND PHARMACEUTICAL USE THEREOF - The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant, 1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a nerve repair, a pharmaceutical composition comprising said binding molecule; and a method of treatment of nerve repair; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with nerve repair. | 2011-01-13 |
20110008335 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds - The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects. | 2011-01-13 |
20110008336 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 2011-01-13 |
20110008337 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 2011-01-13 |
20110008338 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 2011-01-13 |
20110008339 | MONOCLONAL ANTIBODY AND USE THEREOF - An antibody capable of recognizing amyloid β while not recognizing amyloid β precursor proteins, and a method for using the same. | 2011-01-13 |
20110008340 | ANTI-PROPERDIN ANTIBODIES - A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject. | 2011-01-13 |
20110008341 | Polypeptides and methods for making the same - An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence | 2011-01-13 |
20110008342 | COMPOSITIONS OF HUMANIZED NOTCH FUSION PROTEINS AND METHODS OF TREATMENT - This invention provides a fusion protein comprising a single peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder. | 2011-01-13 |
20110008343 | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation - Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate. | 2011-01-13 |
20110008344 | FUSION PARTNER CELL LINE FOR PREPARATION OF HYBRID CELLS EXPRESSING HUMAN ANTIBODIES - This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies. | 2011-01-13 |
20110008345 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 2011-01-13 |
20110008346 | BIOMARKERS FOR CARDIOVASCULAR DISEASE - The present invention relates to a method of diagnosis or prognosis of cardiovascular disease in a subject, said method comprising the steps of detecting the presence of activated endothelial progenitor cells (EPCs) in a sample of a circulation fluid of said subject. The invention further relates to biomarkers for diagnosis or prognosis of cardiovascular disease in a patient, said biomarker comprising the expression product of a gene the expression of which is regulated during vasculogenesis. | 2011-01-13 |
20110008347 | CANCER-RELATED PROTEIN KINASES - The present invention relates to mutant kinase polypeptides and kinase variants selected from the group consisting of AATYK (AATK), ABL1, ACK1, ALK, ARG, AXL, BMX, BRK, BTK, CCK4, CSFR1, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, FAK, FER, FES, FGFR1, FGFR2, FGFR4, FLT3, FRK, FYN, HER2, HER3, HER4, IGF1R, INSR, ITK, JAK1, JAK2, JAK3, LCK, LMTK2 (AATYK2/BREK), LYN, MATK, MER, MET, NTRK1, NTRK2, NTRK3, PDGRFA, PDGFRB, PTK-9, PYK2, RET, RON, ROR1, ROR2, ROS, RYK, STYK, SYK, TEC, TEK, TIE, TNK1, TXK, TYK2, TYRO3, VEGFR1, VEGFR2, VEGFR3, YES1, and ZAP70, nucleotide sequences encoding the mutant kinase polypeptides and kinase variants, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions, including the screening for and identification of novel protein kinase modulators. | 2011-01-13 |
20110008348 | SOLUBLE FRAGMENTS OF INFLUENZA VIRUS PB2 PROTEIN CAPABLE OF BINDING RNA-CAP - A plastic container includes an upper portion having a mouth defining an opening into the container. A shoulder region extends from the upper portion. A sidewall portion extends between the shoulder region and a base portion. The base portion closes off an end of the container. A vacuum panel region defined in part by at least two vacuum panels. Each of the vacuum panels are movable to accommodate vacuum forces generated within the container resulting from heating and cooling of its contents. The vacuum panel region occupies an area outboard of the sidewall portion. | 2011-01-13 |
20110008349 | Hypoxia Induced Mitogenic Factor - We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II. | 2011-01-13 |
20110008350 | EXTRACELLULAR TARGETS FOR ALZHEIMER'S DISEASE - The present invention relates to the field of neurological disorders and more particularly to the field of Alzheimer's disease. Specifically, the invention provides extracellular targets for Alzheimer's disease selected from the tetraspanin web family and associated proteins. In addition, methods are provided for the use of siRNAs and antibodies against the targets for inhibition of amyloid-beta production and, hence, for the treatment of Alzheimer's disease. | 2011-01-13 |
20110008351 | ANTICOMPLEMENT POLYPEPTIDES OF IXODES RICINUS - An isolated and purified polypeptide is obtained from tick salivary glands and presents more than 75% sequence identity with at least a sequence selected from the group consisting of SEQ. ID. NO. 1. | 2011-01-13 |
20110008352 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 2011-01-13 |
20110008353 | IDENTIFICATION OF ASTROVIRUS VA1 ASSOCIATED WITH GASTROENTERITIS IN HUMANS - Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus. | 2011-01-13 |
20110008354 | ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 2011-01-13 |
20110008355 | ANTI-FLT3 ANTIBODIES - The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate. | 2011-01-13 |
20110008356 | IL-17 HETEROMERIC RECEPTOR COMPLEX - The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. | 2011-01-13 |
20110008357 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 2011-01-13 |
20110008358 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II - Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (K | 2011-01-13 |
20110008359 | MONOCLONAL ANTIBODIES AGAINST ANGPTL4 - Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided. | 2011-01-13 |
20110008360 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 2011-01-13 |
20110008361 | Treatment Method - A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance. | 2011-01-13 |
20110008362 | ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE - The present invention relates to compositions for ameliorating the symptoms of celiac disease or gluten sensitive enteropathy comprising egg yolk antibodies against gluten, including gliadin, high molecular glutenin, low molecular glutenin and mixtures of the three peptides. The antibodies may be produced by immunizing laying hens with immunogenic preparations of gluten and harvesting the eggs and egg yolks. | 2011-01-13 |
20110008363 | ERYTHROPOIETIN VARIANTS - The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system. | 2011-01-13 |
20110008364 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 2011-01-13 |
20110008365 | METHODS OF TREATING SCLERODERMA - The present invention relates to methods for treating/ameliorating seleroderma and associated symptoms. | 2011-01-13 |
20110008366 | INHIBITION OF VERSICAN WITH SIRNA AND OTHER MOLECULES - The present invention provides methods of treating disease or condition in a subject in need thereof, comprising administering the subject a versican inhibitor in an amount effective to treat the disease or condition. Example diseases or conditions include, but are not limited to, fibrotic disease such as fibrotic lung disease, restenosis such as arterial restenosis, atherosclerosis, cancer, and inflammatory disease. Compounds and compositions for carrying out such a method are also described. | 2011-01-13 |
20110008367 | ANTI-VEGF ANTIBODY - An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. | 2011-01-13 |
20110008368 | METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER - Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX4OL. OX4OL inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX4OL is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX4OL modulates the generation and function of IL-10 producing Foxp3 | 2011-01-13 |
20110008369 | PD-1 BINDING PROTEINS - The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer. | 2011-01-13 |